News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer
Elvina Almuradova/X
Nov 24, 2024, 18:03

Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer

Elvina Almuradova, Associate Professor at Medicana Health Group, shared a post on X:

“FDA approves Zanidatama for HER2+ biliary tract cancer based on HERIZON-BTC-01 trial results:

  • ORR: 52%
  • DOR: 14.9 months
  • First dual HER2-targeted bispecific antibody for BTC

The confirmatory Phase III trial is ongoing.”

Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer

Read more about the FDA approval of Zanidatama on oncodaily.com.

More posts featuring Elvina Almuradova.

Biliary tract cancer cancer Elvina Almuradova FDA HER2+ biliary tract cancer HERIZON-BTC-01 OncoDaily Oncology Zanidatama Ziihera
Special Coverage
Blog
Jan 28, 2025, 20:25
Hung Trinh: Direct in vivo CAR T cell engineering
Career
Jan 28, 2025, 19:39
Nina Bhardwaj - Candidate for the Nominating Committee of AACR
Blog
Jan 28, 2025, 17:24
Sohila Karem: Attending the Cairo BGICC has been an incredibly enriching experience
Science
Jan 28, 2025, 17:24
Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection
Blog
Jan 28, 2025, 17:24
Estela Rodriguez: Dear FDA, clinical trial diversity is not DEI
Blog
Jan 28, 2025, 17:24
Estela Rodriguez: Registration is open for the 22nd Annual PER Winter Lung Cancer Conference
Science
Jan 28, 2025, 17:24
Manel Esteller: Thrilled to introduce our article on mapping the "Hallmarks of Cancer" in human primary tumors
Blog
Jan 28, 2025, 17:23
Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25
Insight
Jan 28, 2025, 17:20
Pashtoon Kasi: Very intriguing to see differences of single agent PD1 vs combination with CTLA4
Blog
Jan 28, 2025, 17:20
Melanoma clinical trial ME17 is officially open for enrollment in Canada - Canadian Cancer Trials Group
Blog
Jan 28, 2025, 17:19
EIOC Journal Club virtual roundtable discussion on the Treatment of Endometrial Cancer
Blog
Jan 28, 2025, 17:18
Pashtoon Kasi: Positive thing to look at ASCO each year is the “incremental” gains in survival